Multicenter Single-arm Trial to Investigate Clinical Outcomes When Cohealyx™ is Used for Full Thickness Wounds

Eligibility Criteria

• 1. The patient has a staged surgical procedure planned that requires autografting for treatment of a full thickness wound.
• 2. The patient is hospitalized within 3 days of injury.
• 3. The surgical excision occurs within 5 days post-injury.
• 4. The patient (or parent/guardian/legally authorized representative) is willing and able to comply with all study procedures and visit schedule.
• 5. The patient (or parent/guardian/legally authorized representative) agrees to abstain from any other treatment of the study area or enrollment in another interventional clinical trial for the duration of his/her participation in the study (26 weeks post-autografting).
• 6. In the opinion of the investigator, the patient (or parent/guardian/legally authorized representative) must be able to:
• 1. Understand the full nature and purpose of the study, including possible risks and adverse events,
• 2. Understand instructions, and
• 3. Provide voluntary written informed consent
• 1. Clinical signs of wound infection at study area.
• 2. The patient has a medical condition, is using medications or receiving treatments (e.g., immune deficiency) that may compromise patient safety or the trial evaluations or objectives.
• 3. The patient is unable to understand English or Spanish.
• 4. The patient has a known hypersensitivity to bovine-derived collagen, porcine, or aloe vera materials.
• 5. Presence of a medical condition where the patient's life expectancy is less than 1 year (e.g., malignancy).